Ironwood Pharmaceuticals, Inc. Just Beat EPS By 11%: Here's What Analysts Think Will Happen Next

A week ago, Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) came out with a strong set of quarterly numbers that could potentially lead to a re-rate of the stock. It was overall a positive result, with revenues beating expectations by 9.4% to hit US$133m. Ironwood Pharmaceuticals reported statutory earnings per share (EPS) US$0.36, which was a notable 11% above what the analysts had forecast. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

Taking into account the latest results, the most recent consensus for Ironwood Pharmaceuticals from four analysts is for revenues of US$494.1m in 2027. If met, it would imply a major 23% increase on its revenue over the past 12 months. Per-share earnings are expected to leap 46% to US$1.32. Yet prior to the latest earnings, the analysts had been anticipated revenues of US$494.1m and earnings per share (EPS) of US$1.32 in 2027. So it's pretty clear that, although the analysts have updated their estimates, there's been no major change in expectations for the business following the latest results.

View our latest analysis for Ironwood Pharmaceuticals

It will come as no surprise then, to learn that the consensus price target is largely unchanged at US$6.10. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. There are some variant perceptions on Ironwood Pharmaceuticals, with the most bullish analyst valuing it at US$10.00 and the most bearish at US$3.70 per share. So we wouldn't be assigning too much credibility to analyst price targets in this case, because there are clearly some widely different views on what kind of performance this business can generate. As a result it might not be a great idea to make decisions based on the consensus price target, which is after all just an average of this wide range of estimates.

These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Ironwood Pharmaceuticals' past performance and to peers in the same industry. For example, we noticed that Ironwood Pharmaceuticals' rate of growth is expected to accelerate meaningfully, with revenues forecast to exhibit 18% growth to the end of 2027 on an annualised basis. That is well above its historical decline of 4.6% a year over the past five years. Compare this against analyst estimates for the broader industry, which suggest that (in aggregate) industry revenues are expected to grow 22% annually. So it looks like Ironwood Pharmaceuticals is expected to grow at about the same rate as the wider industry.

The Bottom Line

The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. They also reconfirmed their revenue estimates, with the company predicted to grow at about the same rate as the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. At Simply Wall St, we have a full range of analyst estimates for Ironwood Pharmaceuticals going out to 2028, and you can see them free on our platform here..

However, before you get too enthused, we've discovered 3 warning signs for Ironwood Pharmaceuticals (2 are a bit concerning!) that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.